Calton & Associates’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
VCM
VPM
Calton & Associates's BMY Position: Q1 2026 in Review
Calton & Associates sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 6,716 shares — an estimated $362K sold.
Calton & Associates first reported a position in BMY in Q4 2017 and held it in 22 quarters. The position peaked at $1.11M in Q1 2018. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Calton & Associates reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
- Calton & Associates sold 6,716 Bristol-Myers Squibb shares in Q1 2026, an estimated $362K.
- Calton & Associates first reported a position in Bristol-Myers Squibb in Q4 2017 and held it in 22 quarters.
- Calton & Associates's Bristol-Myers Squibb position peaked at $1.11M in Q1 2018.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Calton & Associates's 13F filing for Q1 2026, filed 13 May 2026.